You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Absci and Generate say they use AI to make drugs. Do they?
Awesome story alert: In the race to use novel computational techniques to develop drugs, a number of companies have declared, perhaps prematurely, that their experimental compounds are developed by artificial intelligence. In a new deep dive, STAT’s Brittany Trang examines the efforts of Generate Biomedicines and Absci, and finds that both companies hype their AI abilities in ways that are emblematic of how “AI pharma and biotech companies’ breathless claims can potentially mislead anyone not intimately familiar with the details of drug development, or machine learning.”
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.